Androgens and prostate disease Cooper LA, Page ST - Asian J Androl - 0 views
-
intraprostatic androgens are not concomitantly increased when serum androgen levels are raised.
-
The "saturation model" proposes that the prostate is sensitive to very low concentrations of circulating androgens, but that once maximal AR binding is achieved, which occurs at relatively low concentrations of circulating T, further increases in serum T have little impact
-
men with metastatic prostate cancer given T who had been previously treated with castration had worsening of disease, whereas those without prior castration did not
- ...3 more annotations...
-
Nice review of the mixed data on Testosterone and Prostate disease. It is clear that Testosterone does not precipitate Prostate cancer. The intraprostatic hormone milieu likely is different than that present in the serum. No surprise there. 5alpha reductase decreases Prostate volume, PSA, and low-grade Prostate cancer, but actually increases aggressive Prostate cancer. Supraphysiologic doping in young men associated with no increase in Prostate disease. PSA no longer to be followed in men < 55. Mortality rate not changed. PSA change of 1.4 ng/ml is appropriate for additional Prostate evaluation. Testosterone therapy on average increased 0.5 ng/ml. Still, no mention of aromatase activity in this article. Why is it that hormone sensitive disease in men is only with regards to androgens and women estrogen.